More on B
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $34.84 |
|
|||
| Open | $34.26 | ||||
| 52 Wk High | $44.27 | ||||
| 52 Wk Low | $30.07 | ||||
| Day High | $35.22 | ||||
| Day Low | $34.03 | ||||
| P/E | 26.66 | ||||
| EPS | $1.31 | ||||
| Volume | 8,870,284 | ||||
- Barrick Gold (ABX:CN) (B) PT Lowered to Cdn$90 at Stifel
- Barrick Gold (ABX:CN) (B) PT Lowered to Cdn$55 at Barclays
- Barrick Mining (B) PT Lowered to $39 at Barclays
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- Barrick Mining (B) PT Lowered to $57 at Scotiabank
- FDA clears Leqembi Iqlik subcutaneous shot as Alzheimer's start dose
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- Barrick to Report Second Quarter 2026 Results on August 10
- Barrick Mining (B) PT Lowered to $61 at Bernstein SocGen Group
Entities mentioned with B
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- Show More...
